Silybin
Half-Life (t½) PO: 6h · IV: 6h
Formula C25H22O10
Molecular Weight 482.44 g/mol Pharmacological Mechanism Principal flavonolignan in the silymarin complex from Silybum marianum. Hepatoprotective via free-radical scavenging, hepatocyte membrane stabilization, inhibition of CYP3A4/P-gp (clinical DDI risk), and Amanita phalloides poisoning antidote (IV silibinin = Legalon SIL). Mixed silybin A + B diastereomers in extracts.
Half-Life & Elimination Curve (PO: 6h · IV: 6h) 100% 50% 25% 12.5% 0% 0h 0×t½ 6h 1×t½ 12h 2×t½ 18h 3×t½ 24h 4×t½ 30h 5×t½ 0×t½ (0h): 100% remaining (~72.1 µg/L) 1×t½ (6h): 50% remaining (~36.1 µg/L) 2×t½ (12h): 25% remaining (~18 µg/L) 3×t½ (18h): 12.5% remaining (~9.01 µg/L) 4×t½ (24h): 6.3% remaining (~4.51 µg/L) 5×t½ (30h): 3.1% remaining (~2.25 µg/L) Plasma (PO) t½ Decay (6h)
0×t½ 0h 100% (72.1 µg/L) 1×t½ 6h 50% (36.1 µg/L) 2×t½ 12h 25% (18 µg/L) 3×t½ 18h 12.5% (9.01 µg/L) 4×t½ 24h 6.3% (4.51 µg/L) 5×t½ 30h 3.1% (2.25 µg/L) Dosing Guidelines Oral (PO): Typical 280 mg (Range: 60–600 mg)Intravenous (IV): Typical 500 mg (Range: 100–1000 mg)Pharmacokinetic Parameters Oral (PO): Bioavailability (F): 4% · Volume of Distribution (Vd): 100 L · Absorption (ka): 0.5 h⁻¹ (t½ka ≈ 1.39h) [PMID 1572758 ]Intravenous (IV): Bioavailability (F): 100% · Volume of Distribution (Vd): 100 L [PMID 1572758 ]Target Organ Systems Notes Loram 2007 + others — oral F is very low (~1-4%); silybin-phytosome (Siliphos) and silibinin meglumine improve absorption ~10x.
Chemical Structure & Identifiers InChIKey: SEBFKMXJBCUCAI-PQVVKJAFSA-NSMILES: COC1=C(C=CC(=C1)[C@H]2[C@@H](OC3=C(O2)C=C(C=C3)[C@H]4[C@@H](C(=O)C5=C(C=C(C=C5O4)O)O)O)CO)OReferences Directory Compounds Registry Human Biology Hub